These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 16451169)
1. Validity and new malignant hyperthermia diagnostic procedures. Gerbershagen MU; Wappler F Acta Anaesthesiol Scand; 2006 Jan; 50(1):127; author reply 127-8. PubMed ID: 16451169 [No Abstract] [Full Text] [Related]
2. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia. Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621 [TBL] [Abstract][Full Text] [Related]
3. Current diagnostic methods of malignant hyperthermia: an evaluation. Ording H Acta Anaesthesiol Belg; 1990; 41(2):103-6. PubMed ID: 2371801 [No Abstract] [Full Text] [Related]
4. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Larach MG Anesth Analg; 1989 Oct; 69(4):511-5. PubMed ID: 2675676 [No Abstract] [Full Text] [Related]
5. Malignant hyperthermia in humans--standardization of contracture testing protocol. Melton AT; Martucci RW; Kien ND; Gronert GA Anesth Analg; 1989 Oct; 69(4):437-43. PubMed ID: 2782643 [TBL] [Abstract][Full Text] [Related]
13. Dantrolene and caffeine contracture test. Lambert W Can Anaesth Soc J; 1980 May; 27(3):304-5. PubMed ID: 7378871 [No Abstract] [Full Text] [Related]
14. Dantrolene and caffeine contracture test. Rosenberg H Can Anaesth Soc J; 1980 May; 27(3):303-4. PubMed ID: 7378870 [No Abstract] [Full Text] [Related]
15. [Malignant hyperthermia: difficulty in diagnosing susceptibility in Spain]. Montes A; Ramos R; Trillo L; Silva T; Puig MM Rev Esp Anestesiol Reanim; 1999 Mar; 46(3):130-2. PubMed ID: 10228380 [No Abstract] [Full Text] [Related]
16. A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia. Tollefson G J Clin Psychopharmacol; 1982 Aug; 2(4):266-70. PubMed ID: 6126494 [No Abstract] [Full Text] [Related]
17. Halothane-succinylcholine induced masseter spasm: indicative of malignant hyperthermia susceptibility? Flewellen EH; Nelson TE Anesth Analg; 1984 Jul; 63(7):693-7. PubMed ID: 6731899 [No Abstract] [Full Text] [Related]
18. Combined caffeine-halothane test for malignant hyperthermia. Nelson TE Br J Anaesth; 1993 May; 70(5):597-8. PubMed ID: 8318343 [No Abstract] [Full Text] [Related]
19. A new screening test for susceptibility to malignant hyperpyrexia. Ellis FR; Harriman DG Br J Anaesth; 1973 Jun; 45(6):638. PubMed ID: 4718256 [No Abstract] [Full Text] [Related]
20. Diagnosis of malignant hyperthermia: implications for the military. Biscardi HM; Muldoon SM; Condon BF Mil Med; 1985 Jun; 150(6):293-6. PubMed ID: 3927188 [No Abstract] [Full Text] [Related] [Next] [New Search]